Differential diagnosis of neurodegenerative dementias using metabolic phenotypes on F-18 FDG PET/CT
- PMID: 24571830
- PMCID: PMC4202838
- DOI: 10.15274/NRJ-2014-10002
Differential diagnosis of neurodegenerative dementias using metabolic phenotypes on F-18 FDG PET/CT
Abstract
Positron emission tomography (PET) imaging with F-18 fluorodeoxyglucose (FDG) can be used as a downstream marker of neuronal injury, a hallmark of neurodegenerative dementias. Characteristic patterns of regional glucose metabolism have been used to classify the dementia subtypes, namely Alzheimer's dementia (AD), frontotemporal dementia (FTD), diffuse Lewy body (DLBD) and vascular dementia (VD). We undertook this study to assess the utility of FDG-PET in the differential diagnosis of dementia subtypes. One hundred and twenty-five patients diagnosed with dementia were referred from cognitive disorders and memory clinics of speciality neurology centres for the FDG-PET study. Imaging-based diagnosis of dementia type was established in 101 patients by visual assessment of individual scans by a PET physician blinded to the clinical diagnosis. The results were compared with an 18-month follow-up clinical assessment made by the specialist neurologist. Concordance of visual evaluation of FDG-PET scans with clinical diagnosis of the dementia type was achieved in 90% of patients scanned. This concordance was 93.4% for AD, 88.8% for FTD, 66.6% for DLBD and 92.3% for the other dementia syndromes. FDG-PET performed after the initial work-up of dementias is useful for supporting the clinical diagnosis of dementia subtype.
Keywords: AD; DLBD; FDG-PET; FTD; vascular dementia.
Figures



Similar articles
-
Impact of molecular imaging on the diagnostic process in a memory clinic.Alzheimers Dement. 2013 Jul;9(4):414-21. doi: 10.1016/j.jalz.2012.07.003. Epub 2012 Nov 16. Alzheimers Dement. 2013. PMID: 23164552 Clinical Trial.
-
Evaluating 2-[18F]FDG-PET in differential diagnosis of dementia using a data-driven decision model.Neuroimage Clin. 2020;27:102267. doi: 10.1016/j.nicl.2020.102267. Epub 2020 Apr 24. Neuroimage Clin. 2020. PMID: 32417727 Free PMC article.
-
Syndrome-specific patterns of regional cerebral glucose metabolism in posterior cortical atrophy in comparison to dementia with Lewy bodies and Alzheimer's disease--a [F-18]-FDG pet study.J Neuroimaging. 2015 Mar-Apr;25(2):281-288. doi: 10.1111/jon.12104. Epub 2014 Mar 5. J Neuroimaging. 2015. PMID: 24593796
-
Positron emission tomography imaging in dementia.Br J Radiol. 2007 Dec;80 Spec No 2:S160-7. doi: 10.1259/bjr/97295129. Br J Radiol. 2007. PMID: 18445746 Review.
-
Non-Alzheimer types of neurodegenerative dementia: clinical and 18F-FDG-PET/CT pictures.Nucl Med Commun. 2014 Nov;35(11):1085-92. doi: 10.1097/MNM.0000000000000191. Nucl Med Commun. 2014. PMID: 25162962 Review.
Cited by
-
Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals.Int J Mol Sci. 2020 Apr 30;21(9):3158. doi: 10.3390/ijms21093158. Int J Mol Sci. 2020. PMID: 32365768 Free PMC article. Review.
-
Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease.Int J Mol Sci. 2020 Aug 30;21(17):6279. doi: 10.3390/ijms21176279. Int J Mol Sci. 2020. PMID: 32872643 Free PMC article. Review.
-
The Clinical Spectrum of Young Onset Dementia Points to Its Stochastic Origins.J Alzheimers Dis Rep. 2021 Aug 26;5(1):663-679. doi: 10.3233/ADR-210309. eCollection 2021. J Alzheimers Dis Rep. 2021. PMID: 34632303 Free PMC article.
-
The mechanism of lipopolysaccharide administration-induced cognitive function impairment caused by glucose metabolism disorder in adult rats.Saudi J Biol Sci. 2019 Sep;26(6):1268-1277. doi: 10.1016/j.sjbs.2019.06.017. Epub 2019 Jul 2. Saudi J Biol Sci. 2019. PMID: 31516357 Free PMC article.
-
Illustrated Neuropathologic Diagnosis of Alzheimer's Disease.Neurol Int. 2023 Jul 12;15(3):857-867. doi: 10.3390/neurolint15030054. Neurol Int. 2023. PMID: 37489360 Free PMC article.
References
-
- Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain. 2007;130(Pt 10):2616–2635. doi: 10.1093/brain/awm177. - DOI - PubMed
-
- Minoshima S, Foster NL, Sima AA, et al. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with Autopsy confirmation. Ann Neurol. 2001;50(3):358–365. doi: 10.1002/ana.1133. - DOI - PubMed
-
- Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286(17):2120–2127. doi: 10.1001/jama.286.17.2120. - DOI - PubMed
-
- Albin RL, Minoshima S, D’Amato CJ, et al. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996;47(2):462–466. doi: 10.1212/WNL.47.2.462. - DOI - PubMed
-
- Ishii K, Sakamoto S, Sasaki M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med. 1998;39(11):1875–1878. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical